Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia

Summary

dministration of heparin in the secondary prevention of placental vascular complications is still experimental. In women with a previous severe pre-eclampsia, we investigated the effectiveness of enoxaparin, a low-molecular-weight heparin, in preventing these complications. Between January 2000 and January 2010, 224 women from the NOHA First cohort, with previous severe pre-eclampsia but no foetal loss during their first pregnancy and negative for antiphospholipid antibodies, were randomised to either a prophylactic daily dose of enoxaparin starting from the positive pregnancy test (n=112), or no enoxaparin (n=112). The primary outcome was a composite of at least one of the following: pre-eclampsia, abruptio placentae, birthweight ≤5^th percen-tile, or foetal loss after 20 weeks. Enoxaparin was associated with a lower frequency of primary outcome: 8.9% (n=10/112) vs. 25 % (28/112), p=0.004, hazard ratio = 0.32, 95% confidence interval (0.16–0.66), p=0.002. Enoxaparin was safe, with no obvious side-effect, no thrombocytopenia nor major bleeding event excess. This pilot study shows that enoxaparin given early during the second pregnancy decreases the occurrence of placental vascular complications in women with a previous severe pre-eclampsia during their first pregnancy.

The pilot randomised controlled NOH-PE trial

Keywords

Pregnancy - pre-eclampsia - placental vascular complications - low-molecular-weight heparin - randomised controlled trial

• References

• 1 Van Rijn BB, Hoeks LB, Bots ML. et al. Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia. Am J Obstet Gynecol 2006; 195: 723-728.
• 2 Dildy III GA, Belfort MA, Smulian JC. Preeclampsia recurrence and prevention. Semin Perinatol 2007; 31: 135-141.
• 3 McDonald SD, Best C, Lam K. The recurrence risk of severe de novo pre-eclampsia in singleton pregnancies: a population-based cohort. Br J Obstet Gynecol 2009; 116: 1578-1584.
• 4 Hernandez-Diaz S, Toh S, Cnattingius S. Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study. Br Med J 2009; 338: b2255
• 5 Chang JJ, Muglia LJ, Macones GA. Association of early-onset pre-eclampsia in first pregnancy with normotensive second pregnancy outcomes: a population-based study. Br J Obstet Gynecol 2010; 117: 946-953.
• 6 Ananth CV, Peltier MR, Chavez MR. et al. Recurrence of ischemic placental disease. Obstet Gynecol 2007; 110: 128-133.
• 7 Duley L, Henderson-Smart DJ, Meher S. et al. Antiplatelet agents for preventing preeclampsia and its complications. Cochrane Database Syst Rev 2007; 2: CD004659
• 8 Rey E, Garneau P, David M. et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost 2009; 7: 58-64.
• 9 Gris JC, Chauleur C, Faillie JL. et al. Enoxaparin for the secondary prevention of placental vascular complications in women with abruption placentae. The pilot randomised controlled NOH-AP trial. Thromb Haemost 2010; 104: 771-779.
• 10 Lissalde-Lavigne G, Fabbro-Peray P, Cochery-Nouvellon E. et al. Factor V Leiden and prothrombin G20210A polymorphisms as risk factors for miscarriage during a first intended pregnancy: the matched case-control 'NOHA first' study. J Thromb Haemost 2005; 3: 2178-2184.
• 11 Cochery-Nouvellon E, Mercier E, Lissalde-Lavigne G. et al. Homozygosity for the C46T polymorphism of the F12 gene is a risk factor for venous thrombosis during the first pregnancy. J Thromb Haemost 2007; 5: 700-707.
• 12 Schulman S, Kearon C, Lissalde-Lavigne G. et al. on behalf of the subcommittee on control of anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Scientific and Standardization Committee Communication. J Thromb Haemost 2005; 3: 692-694.
• 13 Wisser J, Dirschedl P, Krone S. Estimation of gestational age by transvaginal sonographic measurement of greatest embryonic length in dated human embryos. Ultrasound Obstet Gynecol 1994; 4: 457-462.
• 14 Salomon LJ, Duyme M, Crequat J. et al. French fetal biometry: reference equations and comparison with other charts. Ultrasound Obstet Gynecol 2006; 28: 193-198.
• 15 Kulkarni A, Chavan-Gautam P, Mehendale S. et al. Global DNA methylation patterns in placenta and its association with maternal hypertension in pre-eclampsia. DNA Cell Biol 2011; 30: 79-84.
• 16 Chiaffarino F, Ascone GB, Bortulus R. et al. Effects of folic acid supplementation on pregnancy outcomes: a review of randomized clinical trials. Minerva Ginecol 2010; 62: 293-301.
• 17 Mello G, Parretti E, Fatini C. et al. Low-molecular weight heparin lowers the recurence rate of preclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension 2005; 45: 86-91.
• 18 Smith GC, Crossley JA, Aitken DA. et al. Circulating angiogenic factors in early pregnancy and risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol 2007; 109: 1316-1324.
• 19 Hossain N, Schatz F, Paidas MJ. Heparin and maternal fetal interface: why should it work to prevent pregnancy complications?. Thromb Res 2009; 124: 653-655.
• 20 Fluhr H, Sprattle J, Ehrhardt J. et al. Heparin and low-molecular-weight heparins modulate the decidualization of human endometrial stromal cells. Fertil Steril 2010; 93: 2581-2587.
• 21 Yagel S. Angiogenesis in gestational vascular complications. Thromb Res 2011; 127 (Suppl. 03) S64-66.